September 29 - October 01, 2025
Sheraton, Boston, MA
This report highlights the pressing challenges and opportunities faced by pharmaceutical companies in securing and optimizing their supply chains. Key issues include inadequate cold chain management, regulatory compliance complexities, and theft and security threats, with many companies needing substantial improvements in these areas. The findings also reveal a significant gap in preparedness for future technological and regulatory changes, which could impede progress in the industry
LogiPharma USA 2024, in its 19th annual gathering, focused on crucial themes shaping the pharmaceutical industry's future, including digital transformation, sustainability, end-to-end visibility, risk management, DSCSA compliance, improving partnerships, enhancing supply chain security, and workforce development. The event brought together industry leaders to share groundbreaking insights and practical strategies aimed at advancing pharmaceutical supply chains towards greater efficiency, sustainability, and patient-centricity. The knowledge shared during the event is expected to catalyze innovation in the field, helping LogiPharma USA fulfill its mission of driving the pharmaceutical supply chain forward collaboratively.
Medical supply chains are setting the trends with their use of digital and analytics tools across the value chain to drive growth and productivity, improve resilience, and deliver environmental sustainability. Nonetheless, achieving growth and resilience is still a challenge, especially for medical and pharmaceutical organizations that are heavily dependent upon suppliers in disparate regions. This study explores the investments and strategies medical and pharmaceutical companies have and plan to employ to improve their supply chain strategies and build better partnerships with their suppliers to position themselves for long term, sustainable growth.
Healthcare supply chains are catching up toother industries in their digital transformations, providing new opportunities for greater efficiency, better forecasting, more accountability, and end-to-end visibility. But barriers to operationalizing these capabilities remain. Issues with interoperability and serialization are consistent struggles for many pharmaceutical and medical device manufacturers, and internal supply chain teams must be able to prove or realize ROI to justify important technology investments. This guide identifies opportunities for medical and pharmaceutical manufacturers to achieve a future state for their supply chains, including end-to-end visibility, better forecasting, and easier compliance with oncoming industry regulations.